Ossur hf (OSSFF) Earnings Dates, Call Summary & Reports

Q: When does Ossur hf. (OSSFF) report earnings?

Ossur hf. (OSSFF) is schdueled to report earning on Apr 28, 2026, Before Open (Confirmed).

Q: What is Ossur hf. (OSSFF) earnings time?

Ossur hf. (OSSFF) earnings time is at Apr 28, 2026, Before Open (Confirmed).

Q: Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

Q: What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

Q: What is OSSFF EPS forecast?

OSSFF EPS forecast for the fiscal quarter 2026 (Q1) is 0.05.

Compare

13 Followers

Earnings Data

Report Date

Apr 28, 2026

Before Open (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

0.05

Last Year’s EPS

0.03

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 1 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Feb 03, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call communicated multiple clear positives: solid organic growth (6% FY), strong cash generation ($100M FCF, 11% of sales), product and reimbursement milestones, strategic acquisition (Streifeneder) and continued margin targets with guidance for 2026. Headwinds include temporary disruption in Patient Care from integration/rebranding initiatives, softness in Bracing, FX and tariff pressures and flat performance in the Americas. Management expects Patient Care to recover gradually and provided a reasonably constructive 2026 outlook (5%–8% organic growth, 20%–22% EBITDA margin). Overall, the operational and financial progress, cash strength and strategic milestones outweigh near-term execution and external headwinds.

Company Guidance

Embla guided 2026 organic sales growth of 5–8% with an EBITDA margin of 20–22%; key drivers cited are continued momentum in Prosthetics & Neuro Orthotics (including bionic portfolio and expected benefit from U.S. Medicare coverage), rollout of Neuro Orthotics into new markets, a gradual recovery in Patient Care (targeting growth back to at least market rate) and Bracing roughly in line with market. Management flagged several specific headwinds and phasing items to bear in mind: at current FX rates EBITDA is expected to be ~30 basis points lower versus 2025 due to FX, tariffs cost Emba about $2m in Q4 and ~$5–6m in FY‑25 (and a somewhat higher full‑year run rate if unchanged), Patient Care change initiatives impacted COGS/OpEx by ~$2m in Q4 and ~$6m in FY‑25, and the combined effect of Patient Care initiatives, FX and tariffs reduced EBITDA margin by ~3 percentage points in Q4 and ~1.5 points for the full year; Streifeneder integration is expected to be marginally dilutive (~10–20 bps in 2026). Financial posture assumptions include normalized CapEx of ~3–4% of sales, FY‑25 free cash flow of $100m (11% of sales), and year‑end net interest‑bearing debt/EBITDA of 2.4x (inside the 2–3x target) with a new share buyback program in place.

Strategic Acquisition — Streifeneder Majority Investment

Completed majority investment in Streifeneder in September 2025, positioning Embla as a full-range provider in prosthetics, expanding presence in private-pay markets and expected to broaden patient reach; integration progressing and expected to be marginally dilutive (~10–20 bps) to margins in 2026.

Product Innovation and Reimbursement Wins

Launched multiple new solutions in 2025 including Navii and Icon bionic knees, Odyssey iQ bionic support, Pro-Flex LP Junior prosthetic ankle/foot, and Power Knee functional updates; Fior & Gentz received its first U.S. reimbursement code for a microprocessor-controlled knee joint.

Geographic Expansion and Strategic Partnerships

Opened first clinic in Kyiv, Ukraine, and launched a 3-year Iceland Support Mobility in Ukraine initiative in partnership with the Icelandic government to deliver prosthetic care and rehabilitation.

Solid Organic Sales Growth

Full-year 2025 organic sales growth of 6%; reported growth 9% and local-currency growth 7% (including Streifeneder). Q4 sales were $257 million with 7% organic growth and 14% reported growth (including +5 ppt FX and +3 ppt M&A).

Segment Performance — Prosthetics & Neuro Orthotics

Prosthetics and Neuro Orthotics delivered strong performance: 9% organic growth in Q4 and 10% for the full year, driven by EMEA momentum, College Park portfolio (Icon knee, Odyssey iQ) and APAC (Australia).

Regional Strength — EMEA and APAC

EMEA grew 12% organically in Q4 and APAC grew 9%; EMEA strength was broad-based across business areas (excluding bracing) and benefited from new innovations and Streifeneder contribution.

Profitability and Cash Generation

Full-year EBITDA margin was 20% (on par with 2024). Q4 EBITDA margin was 19%. Net profit grew 33% in the quarter and 21% for the full year. Free cash flow was $42M in Q4 (vs $33M prior year) and $100M for full year (11% of sales, up from $77M / 9%).

Capital Allocation and Balance Sheet

CapEx normalized to ~3% of sales (Q4 CapEx $8M). Net interest-bearing debt / EBITDA at year-end was 2.4x, within target 2–3x, enabling initiation of a new share buyback program.

2026 Guidance

Issued guidance for 2026 of 5%–8% organic sales growth and an EBITDA margin target of 20%–22%, with commentary that reaching upper end will require continued Prosthetics & Neuro Orthotics momentum and Patient Care recovery.

Sustainability Recognition

Earned a place among the world’s top 500 companies for pairing strong growth with environmental responsibility for the second consecutive year.

Ossur hf (OSSFF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

OSSFF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Apr 28, 2026	2026 (Q1)	0.05 / -	0.03	―	―	―
Feb 03, 2026	2025 (Q4)	0.05 / 0.06	0.042	38.10% (+0.02)
Oct 21, 2025	2025 (Q3)	0.06 / 0.06	0.051	17.65% (<+0.01)
Jul 22, 2025	2025 (Q2)	0.05 / 0.05	0.047	6.38% (<+0.01)
Apr 29, 2025	2025 (Q1)	0.04 / 0.03	0.02	50.00% (<+0.01)
Feb 05, 2025	2024 (Q4)	0.05 / 0.04	0.046	-8.70% (>-0.01)
Oct 22, 2024	2024 (Q3)	0.04 / 0.05	0.033	54.55% (+0.02)
Jul 23, 2024	2024 (Q2)	0.05 / 0.05	0.038	23.68% (<+0.01)
Apr 23, 2024	2024 (Q1)	0.03 / 0.02	0.024	-16.67% (>-0.01)
Jan 30, 2024	2023 (Q4)	0.04 / 0.05	0.042	9.52% (<+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

OSSFF Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 03, 2026	$5.02	$5.01	-0.20%
Oct 21, 2025	$4.86	$5.10	+4.94%
Jul 22, 2025	$4.64	$4.64	0.00%
Apr 29, 2025	$4.30	$4.40	+2.33%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Ossur hf. (OSSFF) report earnings?

Ossur hf. (OSSFF) is schdueled to report earning on Apr 28, 2026, Before Open (Confirmed).

What is Ossur hf. (OSSFF) earnings time?

Ossur hf. (OSSFF) earnings time is at Apr 28, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is OSSFF EPS forecast?

OSSFF EPS forecast for the fiscal quarter 2026 (Q1) is 0.05.